Pergamum announces that first patient has been dosed with potential new treatment for hard-to-heal wounds

STOCKHOLM – September 11, 2012. Pergamum AB announced today that dosing has
begun in a randomized Phase I/II trial of LL-37 for the treatment of patients
with hard-to-heal venous leg ulcers. Karolinska Development AB is the majority
owner of Pergamum.
"Non-healing wounds are a huge burden for the individual patient and for the
health care system. Today, there are an estimated 15 million patients globally,
and virtually no medical progress has been made over the last few decades", said
Jonas Ekblom, CEO of Pergamum AB. "This clinical trial will allow us to evaluate
a promising new treatment, based on the body’s own immune defense, for patients
with venous leg ulcers. The ultimate goal is to accomplish faster healing and
improved quality of life for patients who typically have a poor prognosis."

In this double blind multicenter study, patients with chronic leg ulcers will be
randomized to receive either placebo or one of three different doses of LL-37.
The primary objective of the trial is to assess the safety and tolerability of
Pergamum’s proprietary formulation of the therapeutic peptide LL-37. The Phase
I/II study is expected to enroll 32 patients. The principal investigator is Dr.
Ola Rollman, associate professor at the Department of Medicine at Uppsala
University, Sweden.

"This is the third drug candidate developed by Pergamum that enters clinical
development. It is primarily a safety study but we will also be able to see
early signs of efficacy”, said Torbjörn Bjerke, CEO of Karolinska Development AB
and Chairman of the Board of Pergamum." The progressing of LL-37 into human
trials is yet another sign of our ability to mature our project portfolio."

For further information, please contact:
Jonas Ekblom, President and CEO, Pergamum AB
Phone: +46 (0)8 470 37 40, e-mail: jonas.ekblom@pergamum.com

Torbjörn Bjerke, CEO, Karolinska Development AB
Phone: +46 (0)72 744 41 23, e-mail: torbjorn.bjerke@karolinskadevelopment.com

TO THE EDITORS

About Pergamum
Pergamum is a biopharmaceutical company specialized in the development of
therapeutic peptides for local application in infections and wounds. Within
Pergamum, companies and projects are managed as fully integrated operating
units. The company’s vision is to develop a portfolio of unique development
programs representing high medical value that ultimately, through global
partnerships, will result in first-in-class and first-in-category products. The
current development pipeline includes three therapeutic peptides, with potential
for use in several medical applications. Please visit our web site:
www.pergamum.com

About Karolinska Development AB
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class science into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP innovations
to the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out-licensing of
products. An exclusive deal flow agreement with Karolinska Institutet
Innovations AB, along with other cooperation agreements with leading Nordic
universities, delivers a continuous flow of innovations. Today, the portfolio
consists of 35 projects, of which 14 are in clinical development. For more
information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be
required to disclose the information provided herein pursuant to the Securities
Markets Act.